Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00595686 · ClinicalTrials.gov registry record · Phase 1
Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies
A Phase 1 study of Hematologic Neoplasms, sponsored by Esanex.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 4
- Study locations
NCT00595686 is a Phase 1 study of Hematologic Neoplasms that has completed, run by Esanex. The registered enrollment target is 25 participants, below the 1,025-participant average among 20 other Hematologic Neoplasms trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT00595686, a Phase 1 study of Hematologic Neoplasms, has completed, sponsored by Esanex.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 4
- Study locations
Study Summary
Hsp90 is a chemical in the body that is involved in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.
Conditions Studied
Interventions
- DRUG SNX-5422
Study Locations (4)
Georgia
- Pfizer Investigational Site - Augusta
North Carolina
- Pfizer Investigational Site - Chapel Hill
Pennsylvania
- Pfizer Investigational Site - Pittsburgh
Tennessee
- Pfizer Investigational Site - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2008-01 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00595686
The ClinicalTrials.gov registry entry for NCT00595686 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,025-participant average among 20 other Hematologic Neoplasms trials with a reported enrollment target (98% lower). The listed sponsor is Esanex, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematologic Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which SNX-5422 is the first listed.
NCT00595686 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Georgia, North Carolina, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00595686 about?
NCT00595686 is a clinical study titled "Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies". Hsp90 is a chemical in the body that is involved in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.
What is the current status of trial NCT00595686?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2008-01. Estimated completion is 2010-05.
What conditions does trial NCT00595686 study?
This clinical trial studies the following conditions: Hematologic Neoplasms.
What interventions are being tested in trial NCT00595686?
The interventions under investigation include: SNX-5422 (DRUG).
Who is sponsoring clinical trial NCT00595686?
This trial is sponsored by Esanex, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00595686 being conducted?
This trial has 4 study locations across Georgia, North Carolina, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
RECRUITING · Phase 1
-
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
RECRUITING · Phase 1
-
Optimizing PTCy Dose and Timing
ACTIVE NOT RECRUITING · Phase 1
-
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.